Off-the-shelf BAFF-targeting CAR T for B‑cell cancers
Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies
['FUNDING_SBIR_2'] · LUMINARY THERAPEUTICS, INC. · NIH-11379617
An off-the-shelf CAR T-cell therapy that uses the BAFF ligand to target B‑cell cancers like mantle cell lymphoma.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LUMINARY THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (MINNEAPOLIS, UNITED STATES) |
| Trial ID | NIH-11379617 on ClinicalTrials.gov |
What this research studies
You would receive a donor-derived (allogeneic) CAR T product made from γδ T cells that are engineered to use the BAFF ligand to find and kill cancerous B cells. The therapy is designed to bind multiple BAFF receptors (BAFF-R, TACI, BCMA) so cancer cells are less able to escape by losing a single antigen. Researchers will test the engineered cells for cancer-killing ability, persistence, and safety in lab and preclinical models while developing manufacturing methods for an off-the-shelf product. If those steps look promising, the approach would be prepared for early clinical testing in patients.
Who could benefit from this research
Good fit: Adults with mantle cell lymphoma or other relapsed/refractory B‑cell malignancies, especially those who have relapsed after CD19-directed therapies, would be the most likely candidates.
Not a fit: People with cancers that are not driven by B cells or who are medically ineligible for cell therapy (for example, severe organ dysfunction or active uncontrolled infection) would not be expected to benefit.
Why it matters
Potential benefit: If successful, this could become a readily available CAR T option that lasts longer and reduces relapse compared with current single-antigen therapies.
How similar studies have performed: CD19-directed CAR T therapies have produced durable remissions in some B‑cell cancers, but BAFF-ligand CARs and allogeneic γδ CAR platforms are novel and currently have limited clinical data.
Where this research is happening
MINNEAPOLIS, UNITED STATES
- LUMINARY THERAPEUTICS, INC. — MINNEAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GIBBONS, HUNTER RAMSDELL — LUMINARY THERAPEUTICS, INC.
- Study coordinator: GIBBONS, HUNTER RAMSDELL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.